Related Experiment Video
Updated: Jun 3, 2025
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Anti-neuroinflammatory and Neuroprotective Effects of T-006 on Alzheimer's Disease Models by Modulating TLR4-Mediated
Haiyun Chen1, Xiao Chang1, Jiemei Zhou1
1School of Pharmacy, Clinical Pharmacy (School of Integrative Pharmacy), Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Introduction:
Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau expression and phosphorylation in AD transgenic mouse models. Recently, T-006 has been proven to dramatically decrease the levels of total Amyloid β (Aβ) peptide and Glial Fibrillary Acidic Protein (GFAP) and suppress the expression of ionized calcium binding adaptor molecule-1 (Iba-1) in APP/PS1 mice. Therefore, we have further investigated the effects of T-006 on neuroinflammation in AD-like pathology.
Methods:
The anti-inflammatory effects of T-006 and its underlying mechanisms were evaluated in Lipopolysaccharide (LPS)-induced AD rats. The potential protective effects against LPS-activated microglia-mediated neurotoxicity were also measured.
Results:
T-006 significantly improved the cognitive impairment in LPS-induced AD rats by inhibiting the microglia/astrocyte activation. Further cellular assays found that T-006 significantly reserved the anomalous elevation of inflammatory cytokines in LPS-induced BV2 microglial cells in a concentration-dependent manner, while T-006 treatment alone showed no effects on the normal cultured cells. T-006 also reduced the levels of Toll-like Receptor 4 (TLR4)/Myeloid Differentiation protein-88 (MyD88)/NF-κB signaling-related proteins in BV2 cells exposed to LPS stimulation. TAK242, which selectively inhibits TLR4, slightly lessened the effects of T-006 in LPS-treatment BV2 cells without significance. Importantly, T-006 protected neurons against LPS-induced neuroinflammation by inhibiting the Reactive Oxygen Species (ROS) production and maintaining mitochondrial function.
Conclusion:
T-006 inhibited TLR4-mediated MyD88/NF-κB signaling pathways to suppress neuroinflammation in the LPS-induced AD rat model.
Insights
T-006, a novel compound, effectively reduces neuroinflammation in Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Neuroinflammation, driven by microglia activation, is a key factor in Alzheimer's Disease (AD) pathogenesis.
- T-006, a tetramethylpyrazine derivative, has previously shown promise in alleviating cognitive deficits and reducing AD biomarkers in mouse models.
- This study investigates T-006's specific effects on neuroinflammation in an AD-like pathology.
Purpose of the Study:
- To evaluate the anti-inflammatory effects of T-006 in a rat model of Alzheimer's Disease.
- To elucidate the underlying mechanisms by which T-006 modulates neuroinflammation.
- To assess the protective effects of T-006 against microglia-mediated neurotoxicity.
Main Methods:
- Lipopolysaccharide (LPS)-induced AD rat model was used to evaluate T-006's anti-inflammatory effects.
- Cellular assays were performed on LPS-induced BV2 microglial cells to measure inflammatory cytokine levels.
- Western blotting was used to analyze the expression of key signaling pathway proteins, including Toll-like Receptor 4 (TLR4)/Myeloid Differentiation protein-88 (MyD88)/NF-κB.
- Neuronal protection was assessed by measuring Reactive Oxygen Species (ROS) production and mitochondrial function.
Main Results:
- T-006 significantly improved cognitive impairment in LPS-induced AD rats by inhibiting microglia and astrocyte activation.
- T-006 dose-dependently reduced inflammatory cytokines in LPS-induced BV2 microglial cells.
- T-006 suppressed the expression of TLR4/MyD88/NF-κB signaling pathway proteins in LPS-stimulated BV2 cells.
- T-006 protected neurons from LPS-induced neuroinflammation by reducing ROS production and preserving mitochondrial function.
Conclusions:
- T-006 demonstrates significant anti-inflammatory properties in an LPS-induced AD rat model.
- The compound acts by inhibiting the TLR4-mediated MyD88/NF-κB signaling pathway.
- T-006 offers potential as a therapeutic agent for Alzheimer's Disease by targeting neuroinflammation.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...